Mabion S.A. (MAB.WA)
PLN 10.9
(-0.18%)
PLN 10.9
(-0.18%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 55.06 Million PLN | 150.08% |
| 2022 | 22.01 Million PLN | 463.02% |
| 2021 | -6.06 Million PLN | 88.9% |
| 2020 | -54.65 Million PLN | 13.62% |
| 2019 | -63.27 Million PLN | 2.09% |
| 2018 | -64.62 Million PLN | -3.61% |
| 2017 | -62.37 Million PLN | -12.33% |
| 2016 | -55.53 Million PLN | -1261.05% |
| 2015 | -4.08 Million PLN | 11.09% |
| 2014 | -4.58 Million PLN | -14.51% |
| 2013 | -4 Million PLN | -69.54% |
| 2012 | -2.36 Million PLN | -26.55% |
| 2011 | -1.86 Million PLN | -595.49% |
| 2010 | 376.94 Thousand PLN | 196.71% |
| 2009 | -389.78 Thousand PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 10.6 Million PLN | -20.96% |
| 2024 Q3 | -15.32 Million PLN | -244.42% |
| 2024 Q1 | 13.42 Million PLN | 54.37% |
| 2023 Q3 | 10.85 Million PLN | -37.88% |
| 2023 Q2 | 17.47 Million PLN | -3.11% |
| 2023 FY | 55.06 Million PLN | 150.08% |
| 2023 Q1 | 18.03 Million PLN | 33.0% |
| 2023 Q4 | 8.69 Million PLN | -19.91% |
| 2022 Q3 | -6.84 Million PLN | -229.53% |
| 2022 Q1 | 7.1 Million PLN | -71.6% |
| 2022 FY | 22.01 Million PLN | 463.02% |
| 2022 Q4 | 13.56 Million PLN | 298.03% |
| 2022 Q2 | 5.28 Million PLN | -25.56% |
| 2021 FY | -6.06 Million PLN | 88.9% |
| 2021 Q4 | 25 Million PLN | 253.14% |
| 2021 Q1 | -14.07 Million PLN | 8.8% |
| 2021 Q3 | -16.33 Million PLN | -268.46% |
| 2021 Q2 | -4.43 Million PLN | 68.52% |
| 2020 Q1 | -16.67 Million PLN | -0.37% |
| 2020 Q4 | -15.43 Million PLN | -51.54% |
| 2020 FY | -54.65 Million PLN | 13.62% |
| 2020 Q3 | -10.18 Million PLN | 17.53% |
| 2020 Q2 | -12.35 Million PLN | 25.94% |
| 2019 Q4 | -16.61 Million PLN | -15.36% |
| 2019 FY | -63.27 Million PLN | 2.09% |
| 2019 Q1 | -14.5 Million PLN | 8.93% |
| 2019 Q2 | -17.74 Million PLN | -22.29% |
| 2019 Q3 | -14.4 Million PLN | 18.82% |
| 2018 Q1 | -14.06 Million PLN | 30.25% |
| 2018 FY | -64.62 Million PLN | -3.61% |
| 2018 Q3 | -11.8 Million PLN | 48.28% |
| 2018 Q2 | -22.82 Million PLN | -62.24% |
| 2018 Q4 | -15.93 Million PLN | -34.97% |
| 2017 Q4 | -20.16 Million PLN | -52.98% |
| 2017 Q3 | -13.18 Million PLN | 9.75% |
| 2017 Q2 | -14.6 Million PLN | -1.3% |
| 2017 Q1 | -14.41 Million PLN | 70.58% |
| 2017 FY | -62.37 Million PLN | -12.33% |
| 2016 Q2 | -13.6 Million PLN | -578.08% |
| 2016 Q1 | -2 Million PLN | -16625.0% |
| 2016 FY | -55.53 Million PLN | -1261.05% |
| 2016 Q4 | -49 Million PLN | -2157.16% |
| 2016 Q3 | -2.17 Million PLN | 84.05% |
| 2015 Q1 | -1.43 Million PLN | 15.21% |
| 2015 Q2 | -532.31 Thousand PLN | 62.83% |
| 2015 FY | -4.08 Million PLN | 11.09% |
| 2015 Q4 | -12 Thousand PLN | 99.43% |
| 2015 Q3 | -2.1 Million PLN | -295.25% |
| 2014 FY | -4.58 Million PLN | -14.51% |
| 2014 Q4 | -1.68 Million PLN | -43.36% |
| 2014 Q3 | -1.17 Million PLN | -14.48% |
| 2014 Q2 | -1.02 Million PLN | -48.48% |
| 2014 Q1 | -693 Thousand PLN | 51.07% |
| 2013 Q1 | -323 Thousand PLN | 71.28% |
| 2013 Q3 | -979 Thousand PLN | 24.05% |
| 2013 Q4 | -1.41 Million PLN | -44.66% |
| 2013 Q2 | -1.28 Million PLN | -299.07% |
| 2013 FY | -4 Million PLN | -69.54% |
| 2012 Q2 | -525 Thousand PLN | -25.0% |
| 2012 Q4 | -1.12 Million PLN | -283.82% |
| 2012 FY | -2.36 Million PLN | -26.55% |
| 2012 Q1 | -420 Thousand PLN | 0.0% |
| 2012 Q3 | -293 Thousand PLN | 44.19% |
| 2011 FY | -1.86 Million PLN | -595.49% |
| 2010 FY | 376.94 Thousand PLN | 196.71% |
| 2009 FY | -389.78 Thousand PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Bioceltix S.A. | -15.81 Million PLN | 448.056% |
| BIOTON S.A. | 15.29 Million PLN | -259.993% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 175.409% |
| Molecure S.A. | -22.1 Million PLN | 349.103% |
| NanoGroup S.A. | -7.9 Million PLN | 796.807% |
| Pharmena S.A. | 34.87 Million PLN | -57.899% |
| Poltreg S.A. | -16.86 Million PLN | 426.539% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 273.595% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 154.544% |
| Synthaverse S.A. | 8.64 Million PLN | -536.764% |
| Urteste S.A. | -6.44 Million PLN | 954.056% |